53 recruiting, 33 not yet recruiting, 13 active not recruiting, 13 completed. 35 Phase 2, 28 Not applicable, 12 Phase 1, 4 Phase 3, 1 Early Phase 1.
Follow Lung Cancer (NSCLC): new trials by email Literature Review of Lung Cancer (NSCLC) trials Research Report on Lung Cancer (NSCLC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 Cemiplimab, Adjuvant chemotherapy - Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Henry Ford Health System | 33 | 2027-01-01 | 2026-07-15 |
| Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC Zipalertinib - EGFR, Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Stanford University | 42 | 2026-11-01 | 2026-09-03 |
| Postoperative Pulmonary Function Assessment Based on Deep Learning Study Segmentectomy, Lobectomy, Bronchoscopic Ablation - Lung Cancer (NSCLC) | Not applicable | Not yet recruiting | Chinese University of Hong Kong | 192 | 2026-11-01 | 2026-10-21 |
| Navigation Bronchoscopy Guided Microwave Ablation Versus SBRT in Early NSCLC Navigation Bronchoscopy-Guided Microwave Ablation, Stereotactic Body Radiotherapy (SBRT) - Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Chinese University of Hong Kong | 100 | 2026-11-01 | 2026-10-21 |
| Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLC Induction chemoimmunotherapy, radiotherapy, Concurrent Chemotherapy - Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 256 | 2026-10-12 | 2026-10-14 |
| Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer PET imaging with ⁸⁹Zr-trastuzumab, Blood sampling for pharmacokinetics - Lung Cancer (NSCLC), HER2 Expression | Phase 1 | Recruiting | The Netherlands Cancer Institute | 20 | 2026-10-02 | 2026-10-20 |
| NUT Project: Nutritional Support in Thoracic Oncology nutritional status - Oncologic Diseases, Lung Cancer (NSCLC) | Recruiting | Casa di Cura Dott. Pederzoli | 100 | 2026-10-01 | 2026-09-14 | |
| BRain-AVOidant Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumor Malignancies Radiation Treatments Using Brain- Avoidant Proton Craniospinal Irradiation (BRAVO- pCSI) - Leptomeningeal Metastasis, Breast Cancer | Phase 2 | Not yet recruiting | University of Miami | 40 | 2026-10-01 | 2026-09-01 |
| Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC Olomorasib, Pembrolizumab - Lung Cancer, Lung Cancer (NSCLC) | Phase 2 | Suspended | UNC Lineberger Comprehensive Cancer Center | 60 | 2026-10-01 | 2026-08-28 |
| CAIX-targeted PET/CT in Solid Tumors 68Ga-CAIX - Malignant Solid Tumors, Clear Cell Renal Cell Carcinoma | Not applicable | Recruiting | Zhongnan Hospital | 100 | 2026-09-21 | 2026-10-13 |
| Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations Surgical Resection - Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 190 | 2026-09-20 | 2026-09-21 |
| First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations Almonertinib, Trastuzumab Rezetecan - Lung Cancer (NSCLC), EGFR Activating Mutation | Phase 2 | Not yet recruiting | Yongsheng Wang | 35 | 2026-09-09 | 2026-08-17 |
| Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer Stereotactic radiation therapy intervention, Surgical intervention - Lung Cancer (NSCLC) | Not applicable | Not yet recruiting | Aarhus University Hospital | 182 | 2026-09-01 | 2026-02-27 |
| Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer [64Cu]CM500, [68Ga]CM500, PET/MR - Bladder Cancer, Glioma | Early Phase 1 | Not yet recruiting | Lumina Pharmaceuticals Inc | 40 | 2026-09-01 | 2026-08-28 |
| Percutaneous Pulsed Electric Field Ablation for Early-Stage NSCLC and Lung Oligometastases: A Safety and Efficacy Study Pulsed Electric Field Ablation - Lung Cancer (NSCLC) | Not applicable | Not yet recruiting | Energenx Medical LTD. | 10 | 2026-09-01 | 2026-09-10 |
| Zusanli (ST36) Electroacupuncture Treatment for Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer Acupuncture, sham acupuncture - Lung Cancer (NSCLC), Immune Checkpoint Blockade | Not applicable | Recruiting | West China Hospital | 82 | 2026-08-31 | 2026-09-02 |
| Multi-Omics Prediction of Radiation Lung Injury in Immunotherapy-Treated Lung Cancer Patients No Intervention: Observational Cohort - Lung Cancer (NSCLC), Lung Cancer (SCLC) | Not yet recruiting | HAN GUANG | 160 | 2026-08-15 | 2026-08-03 | |
| Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC zoldonrasib, Placebo, pembrolizumab - NSCLC, Non-small Cell Lung Cancer | Phase 3 | Recruiting | Revolution Medicines, Inc. | 430 | 2026-08-14 | 2026-08-20 |
| SL-28 for Advanced Solid Tumours SL-28 - Head & Neck Cancer, Pancreas Carcinoma | Phase 1 / Phase 2 | Recruiting | Second Life Therapeutics | 60 | 2026-08-14 | 2026-09-15 |
| GCC 2545- Improving Post-Radiotherapy Respiratory Function Through Sparing Serial and Parallel Components in the Lung SOC Radiation Treatment Planning, INSPIRE Radiation Treatment Planning - Lung Cancer (NSCLC), Radiation | Phase 2 | Not yet recruiting | University of Maryland, Baltimore | 70 | 2026-08-01 | 2026-07-01 |
Showing 20 of 117. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (117) · Lung Neoplasms (117) · Breast Neoplasms (7) · Neoplasms (7) · Esophageal Neoplasms (6) · Adenocarcinoma of Lung (5) · Colorectal Neoplasms (5) · Ovarian Neoplasms (5) · Prostatic Neoplasms (5) · Liver Neoplasms (4) · Melanoma (4) · Motor Activity (4) · Pancreatic Neoplasms (4) · Stomach Neoplasms (4) · Urinary Bladder Neoplasms (4)
Bronchial Neoplasms (117) · Carcinoma, Bronchogenic (117) · Neoplasms by Site (117) · Respiratory Tract Diseases (117) · Respiratory Tract Neoplasms (117) · Thoracic Neoplasms (117) · Lung Diseases (116) · Neoplasms (110) · Neoplasms by Histologic Type (15) · Digestive System Diseases (12) · Digestive System Neoplasms (12) · Gastrointestinal Diseases (12) · Neoplasms, Glandular and Epithelial (12) · Gastrointestinal Neoplasms (11) · Pathological Conditions, Signs and Symptoms (9)
Drug Therapy (8) · Carboplatin (4) · Pemetrexed (4) · pembrolizumab (4) · Anterior Temporal Lobectomy (3) · Blood Specimen Collection (3) · Observation (3) · osimertinib (3) · tislelizumab (3) · Cisplatin (2) · Exercise (2) · Mastectomy, Segmental (2) · Neoadjuvant Therapy (2) · Nutritional Status (2) · Radiosurgery (2)
Sun Yat-sen University (5) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (4) · Chinese University of Hong Kong (3) · Hacettepe University (3) · Peking University Cancer Hospital & Institute (3) · Shanghai Pulmonary Hospital, Shanghai, China (3) · The First Affiliated Hospital of Guangzhou Medical University (3) · Beijing Haidian Hospital (2) · Copenhagen University Hospital, Rigshospitalet (2) · Guangdong Provincial People's Hospital (2) · Revolution Medicines, Inc. (2) · Shanghai Chest Hospital (2) · Shanghai Zhongshan Hospital (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · University Hospital, Tours (2)
China (47) · United States (20) · Italy (7) · Turkey (Türkiye) (5) · Denmark (4) · France (4) · Hong Kong (4) · Australia (3) · Germany (3) · Hungary (3) · Poland (3) · South Korea (3) · Spain (3) · Taiwan (3) · United Kingdom (3)
Amit Sawant, PhD (2) · Yuqing Huang (2) · Calvin Sze Hang Ng (1) · Cezary Piwkowski, MD, Prof. (1) · Chengzhi Zhou, Doctor (1) · David Chien, MD (1) · Dirk Rades, Prof. Dr. med. (1) · Ebru Calik Kutukcu, Professorr (1) · Ferenc Krausz, Prof, PhD (1) · Fred Hausheer, MD, FACP (1)
PMID 33334576, PMID 34975555, PMID 34997503, PMID 36732083, PMID 36773776, PMID 37496366, PMID 39954935, PMID 40791544, PMID 41044356, PMID 41484629, PMID 41526018, PMID 41877338, PMID 42237141
2025 (2), 2014 (1), 2023 (1), R44CA275590 (1)